What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “All participants will receive single subcutaneously of ART101 injection on day 1 .”In the company’s words, NCT07614308 on ClinicalTrials.gov
- Tested for
- Hypertension (HTN)
- Main trialPhase 1
- “This is an open-label, single dose Phase Ib clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of a single subcutaneous injection of ART101 in patients with hypertension. The study plans to include 2 dose groups: ART101 600 mg and 800 mg. It is planned to enroll 8 subjects per group, for a total of 16 subjects. For dose escalation, a Safety Review Committee (SRC) will be established. If a dose group meets the dose escalation termination criteria, or if significant safety events occur during the dose escalation observation…”In the company’s words, NCT07614308 on ClinicalTrials.gov
Other drugs for Hypertension (HTN)
- BaxdrostatAstraZeneca · Phase 3
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- RalinepagUnited Therapeutics · Phase 3
- OrforglipronEli Lilly · Phase 3
- HCP1803-3Hanmi · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 14 Oct 2026 | A Phase Ⅰ b Clinical Study of ART101 Injection | |
| Phase 1Terminated | 30 Apr 2025 | A Study to Evaluate ART101 in Adult Participants With Hypertension |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026